The US Supreme Court has refused to look at the result of a federal lawsuit between GSK and Teva over so-called ‘skinny labels’ for generic drugs, despite a request from t
Amgen has won a crunch appeals court ruling that delays generic competition to its big-selling psoriasis drug Otezla in the US until 2028, although it missed out on gettin
18 months after it opened an investigation into Teva to see if it illegally blocked generic versions of its big-selling multiple sclerosis drug Copaxone, the European Commission has said it
In a dramatic change in fortunes, Novartis has won a major victory in its bid to defend oral multiple sclerosis therapy Gilenya from early generic competition in the US.
While immunotherapy has transformed the treatment of many cancers, it has failed to make much of an impact in advanced ovarian cancer, and AstraZeneca is hoping to change